Novel organometallic palladium(II) complexes [Pd 2 {(C,N)-C 12 H 8 NH 2)} 2 (µ-dppf)Cl 2 ] (2) [Pd 2 {(C,N)-C 12 H 8 NH 2)} 2 (µ-dpp)Cl 2 ] (3) [1,1-bis(diphenylphosphine)-ferrocene (dppf), 1,3-Bis(4-pyridyl)propane (bpp)] have been synthesized, fully characterized by elemental analysis, multi-nuclear (1 H, 31 P{1H}, 13 C{1H}) NMR and IR spectroscopic techniquesand their biological activities such as anti-tumoralactivity and DNA-protein interactions have been investigated. The crystal structure of (2), established by X-ray diffraction, shows that the dppf ligand is bound to the two palladium atoms in bridgedform. The interaction of the complexes with calf thymus DNA (CT-DNA) has been explored by UV-Vis spectroscopy, emission titration and thermal denaturation (T m) methods, which have revealed that these complexes interact with DNA through intercalation mode. Competitive studies with methylene blue (MB) have shown the ability of the complexes to displace the DNAbound MB, suggesting a competition with MB. Furthermore, the microenvironment and the secondary structure of BSA are changed in the presence of the complexes. Competitive binding using Warfarin, Digoxin and site markers, which have definite binding sites, demonstrated that the complexes bind to site I on BSA. Notably, the complexes exhibit significant in vitro selective cytotoxicity against two human cancer cell lines (JURKAT and SKOV3) with IC 50 values varying from 2.3 to 6.7 μM. This indicates that they are more active than cisplatin and showing low cytotoxic activity on normal cells. Finally, molecular modelling studies have been conducted to determine the binding site of the DNA and BSA with the complexes.